CN105079019A - Compound ivermectin vitamin B oral liquid and preparation method thereof - Google Patents
Compound ivermectin vitamin B oral liquid and preparation method thereof Download PDFInfo
- Publication number
- CN105079019A CN105079019A CN201510544083.5A CN201510544083A CN105079019A CN 105079019 A CN105079019 A CN 105079019A CN 201510544083 A CN201510544083 A CN 201510544083A CN 105079019 A CN105079019 A CN 105079019A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- oral liquid
- ivermectin
- full dose
- compound ivermectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a compound ivermectin vitamin B oral liquid and a preparation method thereof. The oral liquid is prepared from the following components in percentage by mass: 0.05 to 2 percent of ivermectin and 0.0005 to 0.02 percent of vitamin B. The compound ivermectin vitamin B oral liquid provided by the invention has the advantages that the antibiotic spectrum is wide; the drug resistance is not easy to generate; the oral liquid has no irritating response to the oral mucous membrane; the absorbing effect of an organism is good; the cure rate is high; the oral liquid is convenient to use, has a better treatment effect and lower cost compared with similar products.
Description
Technical field
The present invention relates to pharmaceutic preparation for livestock technical field, be specifically related to a kind of compound ivermectin vitamin B oral liquid and preparation method thereof.
Background technology
Ivermectin is the one group of Macrolide antiparasitic produced by Avid kyowamycin, is the Macrolide antiparasitic of the wide spectrum be most widely used clinically at veterinary drug at present, efficient, low toxicity.Particularly to the nematicide in family's carcass, epizoa (fly larvae, louse, demodicid mite, Ticks etc.) has special efficacy.Because this medicine has excellent anthelmintic activity and higher safety, so be regarded as the most excellent at present, one of most widely used anti-parasite medicine for animal use.
Ivermectin has fat-solubility, and therefore its pharmacokinetic characteristic has larger apparent volume of distribution and comparatively slow elimination process, and administration for oral administration easily absorbs, and absorption rate is fast.Ivermectin can strengthen invertebrates nerve synapse caudacoria to the permeability of chloride ion, thus the transmission of block nerves signal, finally make neural paralysis, and can animal dead be caused.Ivermectin has very strong selectivity to invertebrates, and therefore this medicine is safer as parasite medicine inside and outside mammiferous antibody.Compared with traditional anti-parasite medicine, the antiparasitic mechanism of action of ivermectin is unique, does not thus produce cross resistance with other class anti-parasite medicine.
Summary of the invention
The invention provides a kind of compound ivermectin vitamin B oral liquid: control domestic animal endoparasite and ectoparasite; Supplement the nutrition of body, the immunity of enhancing body; Cross resistance is not produced with other class antiparasitic; Safe and efficient, easy to use, low price.
For achieving the above object, the invention provides following technical scheme:
The invention discloses a kind of compound ivermectin vitamin B oral liquid, the key component of this oral liquid and mass percent thereof are:
Ivermectin 0.05% ~ 2%
Vitamin B 0.0005% ~ 0.02%
Surplus is solvent for oral use.
Further, described vitamin B is vitamin B
1, vitamin B
2, vitamin B
3, vitamin B
6, vitamin B
12, biotin H, one or more mixing in nicotinic acid or folic acid.
Further, it is as follows that described solvent for oral use specifically forms content: cosolvent 1% ~ 10%, surfactant 5% ~ 15%, antioxidant 0.01% ~ 0.1%, antiseptic 0.0005% ~ 0.005%.
Further, described cosolvent is one or more mixing in isopropyl alcohol, propylene glycol, n-butyl alcohol, isobutanol, sorbitol, ethyl acetate, methyl acetate, ethyl oleate, acetamide, dimethyl formamide or dimethyl acetylamide.
Further, described surfactant is one or more mixing in tween 80, Arlacel-40, Arlacel-80, polyvinylpyrrolidone or polyoxyethylene aliphatic alcohol ether.
Further, described antioxidant is one or more mixing in disodiumedetate, toluene di-tert-butyl phenol, BHA, nor-pair of hydrogen guaiaretic acid and gallic acid and ester thereof.
Further, described antiseptic is one or more mixing in thimerosal, benzoic acid, sodium benzoate or sorbic acid.
The present invention also discloses described compound ivermectin vitamin B oral liquid and preparation method thereof, the cosolvent first getting full dose is put in dosing cylinder, add the ivermectin of full dose while stirring, heated and stirred adds the surfactant of full dose after extremely dissolving completely, add purified water to 60% of full dose after stirring; Get appropriate purified water, add the vitamin B of full dose, antiseptic, antioxidant while stirring, to be added in above-mentioned solution after dissolving completely and to stir, adding pure water to full dose, measure pH value and should be 5.5 ~ 6.5; After the inspection of semifinished product is qualified, by 0.22 μm of water system membrane filtration, fill, lamp inspection, labeling, packaging, obtains compound avermectin biostearin B oral liquid.
Beneficial effect of the present invention is:
The present invention is by ivermectin and water-soluble (vitamin) B reasonable compatibility prescription, effectively can kill a parasite such as carcass interior lines worm and external louse, demodicid mite, simultaneously for animal body provides important water soluble vitamins, control Vitamin B deficiency disease, improves the immunity of body.Therefore, compound ivermectin vitamin B oral liquid of the present invention: domestic animal endoparasite and ectoparasite can be prevented and treated; The nutrition of body can be supplemented; The immunity of energy enhancing body, and do not produce cross resistance with other class antiparasitic, be a kind of highly effective and safe, easy to use, low-cost anti-parasite medicine for animal use.
Detailed description of the invention
In order to make object of the present invention, technical scheme and beneficial effect clearly, will be described in detail the preferred embodiments of the present invention below.
embodiment 1
Component and the mass percent thereof of the compound ivermectin vitamin B oral liquid of the present embodiment are:
Ivermectin 0.08%
Vitamin B
10.0005%
Isopropyl alcohol 4.5%
Tween 80 15%
Gallic acid 0.05%
Sorbic acid 0.001%
Surplus is purified water.
The preparation method of the compound ivermectin vitamin B oral liquid of the present embodiment is: the isopropyl alcohol first getting full dose is put in dosing cylinder, add the ivermectin of full dose while stirring, heated and stirred adds the tween 80 of full dose after extremely dissolving completely, add purified water to 60% of full dose after stirring; Get appropriate purified water, add the vitamin B of full dose while stirring
1, sorbic acid, gallic acid, to be added in above-mentioned solution after dissolving completely and to stir, adding pure water to full dose, measuring pH value and should be 5.5 ~ 6.5; After the inspection of semifinished product is qualified, by 0.22 μm of water system membrane filtration, fill, lamp inspection, labeling, packaging, obtains compound ivermectin vitamin B oral liquid.
embodiment 2
Component and the mass percent thereof of the compound ivermectin vitamin B oral liquid of the present embodiment are:
Ivermectin 0.1%
Vitamin B
120.001%
DETA-2Na0.05%
Propylene glycol 5%
Arlacel-40 10%
Thimerosal 0.001%
Surplus is purified water.
The preparation method of the compound ivermectin vitamin B oral liquid of the present embodiment is: the propylene glycol first getting full dose is put in dosing cylinder, add the ivermectin of full dose while stirring, heated and stirred adds the Arlacel-40 of full dose after extremely dissolving completely, add purified water to 60% of full dose after stirring; Get appropriate purified water, add the vitamin B of full dose while stirring
12, thimerosal, DETA-2Na, to be added in above-mentioned solution after dissolving completely and to stir, adding pure water to full dose, measuring pH value and should be 5.5 ~ 6.5; After the inspection of semifinished product is qualified, by 0.22 μm of water system membrane filtration, fill, lamp inspection, labeling, packaging, obtains compound ivermectin vitamin B oral liquid.
embodiment 3
Component and the mass percent thereof of the compound ivermectin vitamin B oral liquid of the present embodiment are:
Ivermectin 0.05%
Vitamin B
30.005%
Ethyl oleate 8%
Arlacel-80 8%
Toluene di-tert-butyl phenol 0.08%
Sodium benzoate 0.002%
Surplus is purified water.
The preparation method of the compound ivermectin vitamin B oral liquid of the present embodiment is: the ethyl oleate first getting full dose is put in dosing cylinder, add the avilamycin of full dose while stirring, heated and stirred adds the Arlacel-80 of full dose after extremely dissolving completely, add purified water to 60% of full dose after stirring; Get appropriate purified water, add the vitamin B of full dose while stirring
3, sodium benzoate, toluene di-tert-butyl phenol, to be added in above-mentioned solution after dissolving completely and to stir, adding pure water to full dose, measuring pH value and should be 5.5 ~ 6.5; After the inspection of semifinished product is qualified, by 0.22 μm of water system membrane filtration, fill, lamp inspection, labeling, packaging, obtains compound ivermectin vitamin B oral liquid.
embodiment 4
Component and the mass percent thereof of the compound ivermectin vitamin B of the present embodiment are:
Ivermectin 0.07%
Vitamin B
60.01%
Propylene glycol 4%
Dimethyl acetylamide 1%
Polyoxyethylene aliphatic alcohol ether 10%
BHA 0.08%
Thimerosal 0.002%
Surplus is purified water.
The preparation method of the compound ivermectin vitamin B oral liquid of the present embodiment is: propylene glycol and the dimethyl acetylamide of first getting full dose are put in dosing cylinder, add the ivermectin of full dose while stirring, heated and stirred adds the polyoxyethylene aliphatic alcohol ether of full dose after extremely dissolving completely, add purified water to 60% of full dose after stirring; Get appropriate purified water, add the vitamin B of full dose while stirring
6, thimerosal, BHA, to be added in above-mentioned solution after dissolving completely and to stir, adding purified water to full dose, measuring pH value and should be 5.5 ~ 6.5; After the inspection of semifinished product is qualified, by 0.22 μm of water system membrane filtration, fill, lamp inspection, labeling, packaging, obtains compound ivermectin vitamin B oral liquid.
clinical trial:
1, experimental animal
Certain sheep plant totally 192, a large amount of serosity nose juice is flowed out in a sheep nostril of 100%, the incrustation blocking nostril that nares often has secretions and dust to be formed, cause sheep dyspnea, normal sneeze, dehisce time serious to breathe, sheep only rubs on object with nose, performance is painful uneasy, and shaking the head and get rid of head, jumps in original place, impact is searched for food, appearance is become thin, weary weak, is typical oestriasis.
2, test method
(1) test grouping
The ill goat with typical disease is divided into 6 groups at random, often organizes 30.
A group adopts levamisole hydrochloride injection to treat, by 8mg/kg body weight, and cervical region subcutaneous injection.
B group adopts ivermectin oral liquid to treat, by 0.2mg/kg body weight, oral.
C group adopts the oral liquid of embodiment 1 to treat, by 0.2mg/kg body weight, oral.
D group adopts the oral liquid of embodiment 2 to treat, by 0.2mg/kg body weight, oral.
E group adopts the oral liquid of embodiment 4 to treat, by 0.2mg/kg body weight, oral.
F group is blank group, does not give Drug therapy.
(2) outcome record and analysis
Namely after recording medicine there is the percentage rate of dead polypide in the nasal cavity ejecta of 3 days sick sheep; After medication, in two weeks, sheep does not only flow nose juice, honey stomach, and spirit is well judged to recovers normal, its cure rate completely.Result of the test is as shown in table 1.
Table 1 different pharmaceutical treatment oestriasis result
From above result, application levamisole hydrochloride and the oral liquid group of the embodiment of the present invention are in medication after 3 days, and effective percentage of curing the disease is apparently higher than ivermectin oral liquid group and blank group; Sick sheep cure rate in two weeks after medication, the oral liquid group of the embodiment of the present invention 2 is apparently higher than other two groups.The above results shows, after ivermectin and water-soluble (vitamin) B compatibility being used, can significantly improve cure rate, reduces mortality rate, effectively prevents and treats oestriasis.
What finally illustrate is, above preferred embodiment is only in order to illustrate technical scheme of the present invention and unrestricted, although by above preferred embodiment to invention has been detailed description, but those skilled in the art are to be understood that, various change can be made to it in the form and details, and not depart from claims of the present invention limited range.
Claims (8)
1. a compound ivermectin vitamin B oral liquid, is characterized in that: the key component of this oral liquid and mass percent thereof are:
Ivermectin 0.05% ~ 2%
Vitamin B 0.0005% ~ 0.02%
Surplus is solvent for oral use.
2. compound ivermectin vitamin B oral liquid according to claim 1, is characterized in that: described vitamin B is vitamin B
1, vitamin B
2, vitamin B
3, vitamin B
6, vitamin B
12, biotin H, one or more mixing in nicotinic acid or folic acid.
3. compound ivermectin vitamin B oral liquid according to claim 1, it is characterized in that: it is as follows that described solvent for oral use specifically forms content: cosolvent 1% ~ 10%, surfactant 5% ~ 15%, antioxidant 0.01% ~ 0.1%, antiseptic 0.0005% ~ 0.005%.
4. compound ivermectin vitamin B oral liquid according to claim 3, is characterized in that: described cosolvent is one or more mixing in isopropyl alcohol, propylene glycol, n-butyl alcohol, isobutanol, sorbitol, ethyl acetate, methyl acetate, ethyl oleate, acetamide, dimethyl formamide or dimethyl acetylamide.
5. compound ivermectin vitamin B oral liquid according to claim 3, is characterized in that: described surfactant is one or more mixing in tween 80, Arlacel-40, Arlacel-80, polyvinylpyrrolidone or polyoxyethylene aliphatic alcohol ether.
6. compound ivermectin vitamin B oral liquid according to claim 3, is characterized in that: described antioxidant is one or more mixing in disodiumedetate, toluene di-tert-butyl phenol, BHA, nor-pair of hydrogen guaiaretic acid and gallic acid and ester thereof.
7. compound ivermectin vitamin B oral liquid according to claim 3, is characterized in that: described antiseptic is one or more mixing in thimerosal, benzoic acid, sodium benzoate or sorbic acid.
8. the compound ivermectin vitamin B oral liquid described in claim 1 to 7 any one, it is characterized in that: the cosolvent first getting full dose is put in dosing cylinder, add the ivermectin of full dose while stirring, heated and stirred adds the surfactant of full dose after extremely dissolving completely, add purified water to 60% of full dose after stirring; Get appropriate purified water, add the vitamin B of full dose, antiseptic, antioxidant while stirring, to be added in above-mentioned solution after dissolving completely and to stir, adding pure water to full dose, measure pH value and should be 5.5 ~ 6.5; After the inspection of semifinished product is qualified, by 0.22 μm of water system membrane filtration, fill, lamp inspection, labeling, packaging, obtains compound ivermectin vitamin B oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510544083.5A CN105079019A (en) | 2015-08-31 | 2015-08-31 | Compound ivermectin vitamin B oral liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510544083.5A CN105079019A (en) | 2015-08-31 | 2015-08-31 | Compound ivermectin vitamin B oral liquid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105079019A true CN105079019A (en) | 2015-11-25 |
Family
ID=54560950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510544083.5A Pending CN105079019A (en) | 2015-08-31 | 2015-08-31 | Compound ivermectin vitamin B oral liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105079019A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075458A (en) * | 2016-06-08 | 2016-11-09 | 芜湖福民生物药业有限公司 | Moxidectin preparation and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1158251A (en) * | 1996-11-08 | 1997-09-03 | 王玉万 | Animal anti-parasite oral liquor containing avilamycin or envimycin |
| CN103977017A (en) * | 2014-06-03 | 2014-08-13 | 重庆布尔动物药业有限公司 | Anti-parasitic injection for veterinary use and preparation method thereof |
-
2015
- 2015-08-31 CN CN201510544083.5A patent/CN105079019A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1158251A (en) * | 1996-11-08 | 1997-09-03 | 王玉万 | Animal anti-parasite oral liquor containing avilamycin or envimycin |
| CN103977017A (en) * | 2014-06-03 | 2014-08-13 | 重庆布尔动物药业有限公司 | Anti-parasitic injection for veterinary use and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 农业部兽药评审中心 编: "《兽药国家标准汇编：兽医地方标准上升归家标准（第一册）》", 31 December 2010, 中国农业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075458A (en) * | 2016-06-08 | 2016-11-09 | 芜湖福民生物药业有限公司 | Moxidectin preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102697784B (en) | Enrofloxacin injection for livestock and preparation method thereof | |
| CN101953841A (en) | Swine eperythrozoonosis-resisting compound long-acting oxytetracycline injection and preparation method thereof | |
| CN103977017A (en) | Anti-parasitic injection for veterinary use and preparation method thereof | |
| CN101496811B (en) | Soluble and stable tilmicosin composition | |
| CN102228462B (en) | Method for preparing veterinary oxytetracycline-artemisinin injection and clinical application of veterinary oxytetracycline-artemisinin injection | |
| CN101417018B (en) | Preparation method of animal injection capable of clearing away the heat-evil and expelling superficial evils, cooling blood and relieving dysentery | |
| CN105079019A (en) | Compound ivermectin vitamin B oral liquid and preparation method thereof | |
| CN102861100A (en) | Compound injection for treating animal respiratory tracts and preparation method thereof | |
| CN104208062A (en) | High-concentration compound florfenicol injection, and preparation method and application thereof | |
| CN103126982A (en) | Novel veterinary medicament meglumine enrofloxacin injection and preparation method thereof | |
| CN105535406A (en) | Traditional Chinese medicine composition for preventing and treating livestock respiratory disease | |
| CN102755337B (en) | Compound florfenicol injection and preparation method thereof | |
| CN103211818B (en) | Pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and use thereof | |
| CN104771518B (en) | Pharmaceutical composition for resisting inflammation and treating or assisting in treating swine fever and preparation method thereof | |
| CN103550226B (en) | Compound sulfamonomethoxine sodium injection as well as preparation method thereof | |
| CN100548306C (en) | A kind of injection and preparation technology thereof who treats eperythrozoonosis of domestic animal | |
| CN103656320B (en) | For preventing and treating the oral administered compound Chinese medicine preparation of birds anemofrigid cold, influenza | |
| CN104288152A (en) | Compound berberine sulfate injection for veterinary use and preparation method thereof | |
| CN101879179A (en) | Compound Ofloxacin solution and preparation method thereof | |
| CN103099812A (en) | Medicine for treating porcine reproductive and respiratory syndrome and preparation method thereof | |
| CN108403631A (en) | Ten thousand rhzomorph oil mixed suspension injections of tartaric acid Thailand and preparation method thereof | |
| CN105412135A (en) | Compound closantel sodium ivermectin injection liquid for veterinary use | |
| CN111588773B (en) | Traditional Chinese medicine composition for preventing and treating newborn piglet diarrhea through sow medicine taking and application thereof | |
| CN103520699B (en) | A kind of veterinary traditional Chinese medicine antiviral injection and preparation method thereof | |
| CN1985827B (en) | Compound ciprofloxacin injection for animal and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151125 |
|
| WD01 | Invention patent application deemed withdrawn after publication |